" market is a forward looking entity", what does that have to do with when ACT expects any significant revenues?..

Steve,

Still around, anything specific you wanted?..thanks

Is this MORE dilution?




NO

louisa,

scan that link again. West was not CEO back then, he was President and CSO(lanza's job)..Caldwell was CEO..thanks

UPDATED: Chain of Events ARONSON/GORTON

BOLDED: indicates lawsuits in progress
RED indicates yet to be filed

1) Oct of 2007: Aronson filed a lawsuit for $14MM for breach of contract.
(combined action of Aronson and Gorton)

2) March of 2010: Aronson dropped case one day prior to jury trial case dismissed without prejudice

3) April of 2010: ACT filed to recoup about $625K in attorney fees

4) June of 2010: Trial court denied ACT's appeal for attorney fees

5) Aug of 2010: ACT filed in Appellate Court to recoup the $625K

6) June 21, 2011: Apellate court agreed with lower court, ACT denied attorney fees.
Respondent(Aronson) has right to recoup his fees once filed in lower court

7) August 23, 2011: Aronson files with FEDERAL Court for $12,389,000 . Instead of filing under
contract dispute, he has now filed under Securities/Commodities dispute.

8) 08/24/11 Remittitur Filed Back In Trial Court. Upcoming Filing will determine the settlement amount being asked for. Some settlement fees are not negotiable but attorney fees can be asked for too. This is from APPEAL ACT lost to Appellate court

9) August 25, 2011: Gorton files with FEDERAL Court for $3,000,000. Filed cause:
Securities Fraud

Stemcall,

here is a post I made today on I-Cell that should help. Also, this suit
has 2 claims, The ACT claim Plaintiff seeks $12389000

Hopefully this will answer questions for you and others who are asking.

The beef between Aronson and ACT goes way back to the early 2001 range. Aronson
did financing for ACT and never got paid back. A settlement agreement was signed
in 2005 and that didn't get taken care of either. I will bypass all of that and
start with lawsuits and appeals up to today.

1) Oct of 2007: Aronson filed a lawsuit for $14MM for breach of contract.

2) March of 2010: Aronson dropped case one day prior to jury trial case dismissed without prejudice

3) April of 2010: ACT filed to recoup about $625K in attorney fees

4) June of 2010: Trial court denied ACT's appeal for attorney fees

5) Aug of 2010: ACT went to higher court, Apellate, to recoup the $625K

6) June 21, 2011: Apellate court agreed with lower court, ACT denied attorney fees.
Respondent(Aronson) has right to recoup his fees once filed in lower court

7) August 23, 2011: Aronson files with FEDERAL Court for $28MM. Instead of filing under
contract dispute, he has now filed under Securities/Commodities dispute.

New lawsuit filed,



filed in FED Court yesterday
http://dockets.justia.com/docket/massachusetts/madce/1:2011cv11492/138668/

(based on this claim filed in 10Q)
The Company has received a copy of a Creditor’s Claim (the “Claim”) in the amount of $27,909,706 made with the Estate of William Caldwell (“Decedent”), who at the time of his death was the Chief Executive Officer and Chairman of the Board of Directors of the Company. The Claim states that Decedent’s liability arises under a cause of action that the Claimant intends to file in Federal court against the Company for violations of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including Section 10(b) of the Exchange Act and the rules promulgated thereunder. As of the date of the filing of this report, the Company is not aware of any action commenced against it by the Claimant.

In the Claim, the Claimant alleges that in September 2005, he entered into a Settlement Agreement with the Company pursuant to which he received a warrant to purchase shares of the Company’s Common Stock. In the Claim, the Claimant makes several allegations against the Company including that in reliance on misinformation provided to him by the Decedent he exercised his warrant to purchase the Company’s Common Stock at an inflated price and received fewer shares than he was owed by the Company under the terms of his warrant, that the Company breached the Claimant’s warrant by not timely issuing stock after the warrant was exercised, and that the Company failed to provide proper notice of certain events that allegedly triggered the Claimant’s purported rights to additional shares under the warrant. Claimant previously brought an action against the Company, in October 2007, with respect to a dispute over the interpretation of the anti-dilution provisions of the warrant but withdrew this action the day before the trial date

15 million gifted shares and 15 million options..eom

Ridda,


I have been posting fully diluted numbers for some time. Again, the
writing was on the wall. This settlement just pushed up the date is all..

Ridda,

The info below is not correct.

30,585,000 to be payed out in monthly instalments of 3,600,000 every month until the full amount of shares are met according to the agreement.



Pursuant to the Settlement Agreement, upon tender by Midsummer to the Company of warrants held by Midsummer to purchase a total of 20,319,731 shares of the Company’s common stock (the “Warrants”), and duly executed notices of exercise (deemed to occur upon execution of the Settlement Agreement), the Company, to settle errors involving warrant issuances to Midsummer, agreed to (i) deliver to Midsummer an aggregate of 36,000,000 shares of the Company’s common stock (the “Current Shares”), as an exercise of the Warrants in respect of a partial exercise of Warrants, (ii) undertake to issue 30,585,774 additional shares of the Company’s common stock (the “Future Shares”), as an exercise of the remainder of the Warrants within ten days of the date that the Company shall have sufficient authorized and unissued shares of Common Stock (“Authorized Share Increase”) which are not otherwise reserved for issuance for other purposes to enable the Company to issue all of the Future Shares and (iii) issue 3,058,577 shares of the Company’s common stock (the “Additional Future Shares”) for every calendar month elapsed between the date of delivery of the Current Shares and the date following delivery of the Future Shares. The Company and Midsummer provided mutual general releases.

8K filed,

A. Advanced Cell shall (i) deliver to Midsummer an aggregate of 36,000,000 shares (subject to adjustment for reverse and forward stock splits, stock dividends, reclassifications and the like) of Advanced Cell common stock (the “Current Shares”), issuable upon surrender of the Warrants as a cashless exercise of the Warrants in respect of a partial exercise of Warrants, (ii) shall undertake to issue 30,585,774 additional shares (subject to adjustment for reverse and forward stock splits, stock dividends, reclassifications and the like) of Advanced Cell common stock (the “Future Shares”), as a cashless exercise of the remainder of the Warrants within ten days of the date that Advanced Cell shall have sufficient authorized and unissued shares of Common Stock (“Authorized Share Increase”) which are not otherwise reserved for issuance for other purposes to enable Advanced Cell to issue all of the Future Shares and (iii) shall issue 3,058,577 shares (subject to adjustment for reverse and forward stock splits, stock dividends, reclassifications and the like) of Advanced cell common stock (the “Additional Future Shares”) for every calendar month elapsed between the date of delivery of the Current Shares and the date following delivery of the Future Shares pursuant to the term of this Agreement. Advanced Cell shall seek the Authorized Share Increase as soon as reasonably practical, and in any event within 12 months after the date hereof. Upon obtaining the Authorized Share Increase, Advanced Cell shall reserve a sufficient number of shares thereunder in order to issue all of the Future Shares and Additional Future Shares issuable hereunder. Of such shares, the Future Shares are issued in respect of the exercise of the entire unexercised portion of the Warrants and the Additional Future Shares are issued in respect of the delay from the date hereof until the date such Future Shares are freely tradable. This Agreement hereby constitutes a cashless exercise by Midsummer of the Warrants as in effect on the date hereof, and Advanced Cell agrees that no further notices or actions by Midsummer are required. The Company represents and warrants that all the Current Shares and the Future Shares, when issued, will be freely tradable and without restriction pursuant to Rule 144, as in effect on the date hereof. All the Current Shares and Future Shares shall be electronically delivered to the following accounts of Midsummer (81.5% to Midsummer Investment, Ltd. and 18.5% to Midsummer Small Cap Master, Ltd. unless otherwise notified in writing by Midsummer) by DWAC within 48 hours following the execution of this Agreement by all of the parties hereto, in the case of the Current Shares, and within the time period required hereunder, in the case of the Future Shares:
http://www.sec.gov/Archives/edgar/data/1140098/000114420411048204/v232624_ex10-1.htm

both amendments are for S-1 Registrations that were filed back in 2009.
for example, the one for 72MM shares is for the 10 cent warrants we promised to debt holders when we were restructuring under default. We filed 192MM shares back in 2009. many are being exercised at 10 cents. The amendment keeps the registration of those shares alive so when exercised these guys can sell right away..

No, they have nothing to do with that. Both filings are amending information to previously filed Registration statements to keep them effective with the SEC. Meaning, when the shares listed are issued the sellers can sell them immediately if they wish.

NEW : Lanza and Rabin Employment Agreements:


Employment Agreement with Robert P. Lanza, M.D.

On October 1, 2009, the Company entered into an employment agreement with Robert P. Lanza, the Company’s Chief Scientific Officer since October 2007 and effective July 1, 2011, the Company entered into an Amended and Restated Employment Agreement with Mr. Lanza. Pursuant to the Amended and Restated Employment Agreement, the parties agreed as follows:

· Mr. Lanza will continue serve as the Company’s chief scientific officer for a term commencing on July 1, 2011 until September 30, 2013 (subject to earlier termination as provided therein, and extension by mutual written agreement).

· The Company will pay Mr. Lanza a base salary of $440,000 per year, which amount shall increase at the end of each year of the employment agreement, by an amount determined by the board, but by not less than 5% per year. The Company may also pay Mr. Lanza annual bonuses in in the Company’s sole discretion.

· The Company agreed to issue to Mr. Lanza, upon execution of the employment agreement, (i) 15,000,000 shares of common stock (of which 6,000,000 shares will vest on the date of grant, with the balance of 9,000,000 shares vesting in equal installments on the last day of each month commencing on January 31, 2012 and ending on September 30, 2013), (ii) an option to purchase 15,000,000 shares of common stock with an exercise price equal to the closing price on the date of execution (of which 6,000,000 options will vest on the date of grant, with the balance of 9,000,000 options vesting in equal installments on the last day of each month commencing on January 31, 2012 and ending on September 30, 2013).

· If Mr. Lanza’s employment under the employment agreement were to be terminated by the Company without cause (as defined therein), the Company will pay Mr. Lanza severance equal to one year base salary.
__________________________________________________ __________________________________________________ ___________

Employment Agreement with Gary Rabin

Effective December 14, 2010, the Company entered into an employment agreement with Gary Rabin, Chief Executive Officer, Chief Financial Officer, and Chairman of the Board and effective July 1, 2011, the Company entered into an Amended and Restated Employment Agreement with Mr. Rabin. Pursuant to the Amended and Restated Employment Agreement, the parties agreed as follows:

· Mr. Rabin will serve as the Company’s chief executive officer and chief financial officer for a term commencing on July 1, 2011 until December 31, 2013 (subject to earlier termination as provided therein).

· The Company will pay Mr. Rabin a base salary of $500,000 per year, through December 31, 2011, which amount shall increase at the end of each year of the employment agreement, by an amount determined by the board, but by not less than 5% per year.

· The Company agreed to pay Mr. Rabin a retention bonus of $41,667 within 10 days of execution of the employment agreement.

· The Company shall pay Mr. Rabin an annual incentive bonus, which will be calculated by reference to the 10-day volume weighted average price of the Company’s common stock, as set forth therein.

· The Company shall pay Mr. Rabin a performance bonus in amount (not less than $100,000 per year) to be determined by the Compensation Committee of the Board of Directors.

· The Company agreed to issue to Mr. Rabin, upon execution of the agreement, (i) 10,000,000 shares of common stock, (ii) an option to purchase 10,000,000 shares of common stock with an exercise price equal to fair market value on the date of grant, (iii) an option to purchase 5,000,000 shares of common stock with an exercise price of $0.30, and (iv) an option to purchase 5,000,000 shares of common stock with an exercise price of $0.45. The options will vest, and the shares will no longer be subject to the Company’s right to repurchase for aggregate consideration of $1.00, in equal installments on the last day of each calendar quarter commencing on July 1, 2011 and ending on December 31, 2013.

If Mr. Rabin’s employment under the employment agreement were to be terminated by the Company without cause (as defined therein), the Company will pay Mr. Rabin (in addition to unpaid base salary, performance bonus and incentive bonus to the date of termination), a lump sum equal to the aggregate installments of base salary in effect on the date of termination and otherwise payable in respect of the period commencing on the date immediately subsequent to the date of termination and ending on the earlier to occur of the first anniversary of such date and December 31, 2013.
__________________________________________________ __________________________________________________ _________

Director Compensation Arrangements

Non-executive members of the Company's Board of Directors receive (1) an initial grant of 100,000 shares of common stock, (2) an annual grant of 500,000 shares of common stock, (3) an annual grant of 500,000 stock options, (4) an annual retainer of $40,000 (payable quarterly), and (5) a cash payment for attendance at each board meeting in the amount of $2,000 for in-person meetings and $1,000 for telephonic meetings. Regarding members of the Company's Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, the Chair receives a payment of $1,500 per meeting and the regular members receive $1,000 per meeting. Each independent director is entitled to receive payment of the directors' fees in the form of shares of the Company's Common Stock valued at 150% of the actual directors' fees due and payable. The fee structure for the directors was established and approved by the Compensation Committee and ratified by the full Board of Directors effective August 1, 2011.
http://www.sec.gov/Archives/edgar/data/1140098/000114420411045758/v230876_posam.htm

you missed my point, there was NOT a preferred stock comment made on CC,
it was a restricted stock comment as I stated previously.

Spetty,


management has never received any preferred stock.
Restricted stock is what the CC stated. Don't hold
your breath on all options, you cannot get those for
nothing like the gifted grant shares.

interstate,


What is your take on Rabin becoming the CEO?

always expected it, not sure about it.

No idea on your other question..

Riddakilla,


What's your thoughts on answer he gave to the question about the potential/eventual need to draw down capital from the contracts in place and the need to authorize more share in doing so

Well, I expected both to happen and have said that here quite often.


And can you give me the reason for the 4M draw down? Was it to pay the 10 new employees?

The draw was based on paying CHA $800K for Hemangioblast licensing for USA and Canada, plus $2MM in costs to run the program per year(including 10 employees)..

Conference Call,



* Rabin is permanent CEO(real shocker eh louisa?)

* 2 other clinical trial sites coming online

* BOD Erkki Ruoslahti out, 2 new BOD's to be added.

* Lanza signed extended employment contract, employment contracts will be filed soon

* Comments on trials mum as they should be

* No joint venture in EU if CTA approved, will do as we are doing here.

* Paid $800K for Noth America/Canada hemangioblast rights

* Taking on the 10 scientists from SCRMI and research set to cost around $2MM per year

* RS questions were addressed by saying if they did one it will be timed with an event. Rabin no doubt would like the support from institutions and mutual funds frim a big board.

gravityrulz,


The MA09 line has never had NIH approval, it awaits in the NIH pending category along with the 4 NED lines..

yes, you are confused. Try this link and see if it helps you understand.

The early lines developed like MA09..embryo was slated to be discarded
anyway as many are.

"Because the early clinical testing for the retinal cells was conducted on animals using a cell line from an embryo that was discarded, the company is continuing to use that line for its human testing,"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=63168225

Smooth,

Todays filing showed the following was done mid June. An 8K is usually filed when this happens but nobody had any clue until today..ACT has $17MM left to draw on with Socius. Something will have to be done to increase the number of shares or something before this remaining funding can be exercised.

"On June 16, 2011, the Company delivered the second Series C Tranche notice to Socius for delivery of a total of 400 shares under the Series C preferred stock for funding in the amount of $4,000,000."

Smooth,

Here is what Rabin said in March Conference Call.

I just returned from Europe where we had some great meetings. As far as the RPE program goes, it would be highly premature to seek partners early in the phase 1 study as we are hopeful that even though we are dealing with late stage patients, we will soon have data on retinal engraftment of our cells, and thier impact on photorecptor function. If we see no safety issues, and are able to detect some engraftment of our cells to the photoreceptor / Bruch's membrane, we will obviously be dealing from a much stronger valuation and negotiating position. It is quite possible that within about 12 weeks of commencement of the trials, we may have a pretty interesting set of data to evaluate and discuss, covering an early look at a total of 6 patients between the two trials.

Rabin Blog,


July 28, 2011
Posted by Admin


Supporting the Federal Court Ruling Allowing Federal Funding of Embryonic Stem Cell Research

Greetings,

You have probably seen the news that yesterday U.S. District Judge Royce Lambreth ruled that the National Institutes of Health (NIH) guidelines on embryonic stem cell research do not violate federal law, and that he in turn dismissed the legal challenge to such funding that was initiated last year.

ACT is not and never has been dependent on federal funding. However, we believe this ruling is very positive for research in regenerative medicine and for the field of medicine overall, and we support Judge Lambreth’s decision.

This ruling clears away the last remaining obstacle for the NIH in terms of funding of embryonic stem cell research and development, and could potentially directly benefit ACT as well. We have a number of stem cell lines derived using our “embryo-safe” single-cell blastomere technique currently under consideration for NIH funding, and we hope that this ruling will help accelerate funding for stem cell lines such as ours.

In the meantime, we continue with our programs, especially the Phase 1/2 human clinical trials using using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) for Stargardt’s Macular Dystrophy (SMD) and dry age-related Macular Degeneration (Dry AMD).

Thank you.

Gary Rabin
Interim Chairman and CEO
Advanced Cell Technology, Inc.

MID YEAR STATS: volume, pps, os# , mm's


VOLUME:

all numbers rounded off(millions)

January...486
February..132
March.....218
April......169
May.......105
June......110
TOTAL VOLUME MID YEAR: 1.22 Billion
(NOTE: December of 2010 we traded 1.22B shares)

AVERAGE FLOAT #: approx. 1.3 Billion
Float/Volume: Float traded approx. 1 time in 6 months

MARKET MAKERS:
Rank and Percentage of Volume year to date

#1.AUTO...33%
#2..NITE...18%
#3.ETMM...14%
#4..UBSS...11%
These 4 MM's represent 76% of Total Mid Year Trading of 1.22B

Price Per Share Range: .16-.21 adj. close Jan-June

OUTSTANDING SHARE #

December 31, 2010:1.440 Billion
May 31, 2011........1.545 Billion

First 5 Months approx. 105 Million shares added:
averages about 21MM shares per month
7 remaining months equals another 147MM shares

Fully Diluted(Using Treasury Method of in the money warrants and options)
****NOTE Mr. Rabin's description of fully diluted method below.****

107 Million Warrants: (.10-21)
43 Million Stock Options: (.09-.21)

May 31, 2011 OS#: 1.545B plus the diluted # of 150MM plus 147MM added for 7 more months
TOTAL FULLY DILUTED OS#: 1.842B

SIDE BAR NOTES:

The 1.842 B no doubt is quite a bit over the Authorized Share# of 1.75B. Unless the second half of year has substantially less shares issued than the first half of year, the numbers above strongly suggest that the Authorized share # will have to be increased by year end, if not before. The upcoming 10Q will give us the OS# as the first week in August so that will be helpful in a better projection too. Even though
the issuance of shares has dropped offed dramatically since debt holders were paid off, they still add up and inch us closer to the Max authorized.

****Rabin's response to fully diluted numbers via e-mail.
" Fully diluted shares are calculated on the treasury or reverse treasury method, and takes into account warrants and options that are struck at much higher prices (i.e., we have many options and warrants outstanding at exercises/strikes FAR above current market prices), so you must take this into account. So if the stock were trading at $5.00 per share (obviously without giving effect to a reverse split), we would have 190 million shares convertible into common stock (but it is the option value of those options and warrants that is accounted for in fully diluted share count.)"

SOURCES:

OTC Market Statistics
http://www.otcbb.com/asp/tradeact_mv.asp?Issue=actc&searchby=issue&sortby=volume&Month=6-1-2011&downloadname=mv201106.exe&view.x=36&view.y=9
10K
http://www.sec.gov/Archives/edgar/data/1140098/000101376211000631/form10k.htm
10Q
http://www.sec.gov/Archives/edgar/data/1140098/000114420411026867/v221016_10q.htm
S-8
http://www.sec.gov/Archives/edgar/data/1140098/000114420411036482/v226244_s8.htm

the JV split has nothing to do with current price. "My gut" tells me ACT has many things in the pipeline and a long ways to go.

2ez, From 2008 to May of 2010 the ownership was CHA/67% ACT/33%, from May of 2010 until now it has been CHA/60% ACT/40%


(from 10K filing)
On December 1, 2008, the Company and CHA Bio & Diostech Co., Ltd. formed an international joint venture. The new company, Stem Cell & Regenerative Medicine International, Inc. (“SCRMI”), will develop human blood cells and other clinical therapies based on the Company’s hemangioblast program, one of the Company’s core technologies. Under the terms of the agreement, the Company purchased upfront a 33% interest in the joint venture, and will receive another 7% interest upon fulfilling certain obligations under the agreement over a period of 3 years. The Company’s contribution includes (a) the uninterrupted use of a portion of its leased facility at the Company’s expense, (b) the uninterrupted use of certain equipment in the leased facility, and (c) the release of certain of the Company’s research and science personnel to be employed by the joint venture. In return, for a 60% interest, CHA has agreed to contribute $150,000 cash and to fund all operational costs in order to conduct the hemangioblast program. Effective May 1, 2010, the Company was no longer obligated to provide laboratory space to SCRMI, and the Company holds a 40% interest in the joint venture and CHA Bio & Diostech, Ltd. owns a 60% interest. The two partners to the joint venture are in negotiations on further funding of the joint venture, but there can be no assurances that an agreement will be reached. Any financial statement impact at this time is unclear should an agreement not be reached.

2ez,


in the PR yesterday it states that the ownership of the jv is largely unchanged and becoming a licensing entity. What exactly does that mean to you?

It means the joint venture, SCRMI, remains 60%/CHA and ACT/40%
and that SCRMI is no longer a research company but a licensing company, to issue licenses for hemangioblast technoplogy.

I am sure ACT is glad they got full rights to US and Canada, they had worldwide rights prior to JV. I am sure JV focused on the project but I am not convinced ACT couldn't have done it on their own. Water under the bridge.

absolutely no problem louisa, no need to be embarrased by any means..thanks

louisa,

todays PR showed us the change that has taken place. The SCRMI JV that has existed for a long time will still exist but as a licensing company. No more research done at SCRMI. Our employees were transferred back to us. No obligation for ACT to provide Lab space and equipment. We have exclusive rights for Canada and U.S., CHA exclusive to Japan and Korea.
Details of agreement should show up at some point in time.

louisa,

happened Nov 30 2008

effective date for what?..eom

ACT/CHA Biotech...Chronological Events

PART 1: THIS IS JOINT VENTURE MATERIAL

Nov. 30 2008 ..Share Purchase Agreement

ACT purchased 4000 shares of Allied Cell Technology. 1000(25%) shares were held back until certain contingencies were met. ACT had 33% ownership which when remaining shares were transferred ACT retained a 40% ownership as they do today.

In consideration for the 4000 share investment ACT transferred employees, guaranteed lab space and lab equipment for approx. 3 years.

Parties signing this agreement: Allied Cell, signed by President Dr. Hyung-Min Chung ACT, signed by CEO William Caldwell
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-130.htm

Nov. 30, 2008..Sublicense Agreement

This License Agreement is between Allied Cell(now includes ACT) and Cha Biotech. Sublicensor is Allied Cell, Sublicensee is CHA
This sublicense agreement only gave CHA an Exclusive in South Korea
Section 2 here:
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-126.htm
Allied Cell and CHA were signing parties, Dr. Hyung-Min Chung signed both

MY summary based on these two transactions. First of all, I am pretty sure the Exclusive License Agreement between ACT and Allied is missing from public view which for me at least causes most of the confusion. Based on what I can see, SCRMI(the partnership) holds the worldwide exclusive license and CHA received an Exclusive License for South Korea only back in 2008.


PART 2: THIS SECTION APPLIES TO ACT/CHA DEALS...(not part of joint venture)

NOTE: Both Agreements below are for South Korea ONLY. Both agreements allow CHA non-exclusive worldwide rights to sublicense technology for RESEARCH ONLY..NOT FOR THE SALE

March 30, 2009...Exclusive License Agreement with CHA and ACTC RPE Technology
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-128.htm

MAY 8, 2009...
Exclusive License Agreement Cha and ACTC's Single Cell Biopsy Technique
http://sec.gov/Archives/edgar/data/1140098/000114420409040583/v156251_ex10-129.htm

PART 3: THIS SECTION APPLIES TO NEWS TODAY

July 21, 2011...ACT Obtains Exclusive License For Hemangioblast Technology In North America
ACT to Aggressively Pursue Clinical Translation of "Universal" Blood, Platelets and Off-the-Shelf Mesenchymal Stem Cells Derived From Embryonic Stem Cells, Among Other Technologies

Under the terms of the agreement, SCRMI exclusively licenses the rights to its hemangioblast program to ACT for North America (United States and Canada) and to CHA Biotech for Korea and Japan.

The ownership in SCMRI remains largely unchanged between ACT and CHA Biotech, with the joint venture ceasing internal research activity and transitioning to a licensing entity.

Then you should have been talking to your broker where you hold shares or talking with ACT if you have them in certificate form. It is your responsibility to ask if you don't receive.


Who is entitled to vote at the meeting?

Stockholders of record at the close of business on May 9, 2011, the record date for the meeting, are entitled to receive notice of and to participate in the Annual Meeting. As of the record date, the Company had outstanding and entitled to vote 1,542,957,661 shares of common stock. The common stock is the only classes of stock of Advanced Cell that is outstanding and entitled to vote at the Annual Meeting. If you were a stockholder of record of common stock on that record date, you will be entitled to vote all of the shares that you held on that date at the meeting, or any postponements or adjournments of the meeting. Each outstanding share of Advanced Cell common stock will be entitled to one vote on each matter. Stockholders who own shares registered in different names or at different addresses will receive more than one Proxy card. You must sign and return each of the Proxy cards received to ensure that all of the shares owned by you are represented at the Annual Meeting.
http://www.sec.gov/Archives/edgar/data/1140098/000114420411027813/v221776_def14a.htm

SeeYAkblb,


Welcome to ACT and good luck.

Video on ACT website:


Video Gallery

Retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESC) transplanted into patients' eyes in first two clinical trials at Jules Stein Eye Institute at UCLA.
http://www.advancedcell.com/news-and-media/act-media-gallery/retinal-pigment-epithelial-(rpe)-cells-derived-from-human-embryonic-stem-cells/index.asp

I thought Dr. Steven Schwartz flat out gave the best description to date of what is hoped for with regards to the trials, very refreshing for me.